PARP1 inhibition attenuates NAD depletion and protects against experimental and human Atrial Fibrillation

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of Histone Deacetylase-6 Induces Contractile Dysfunction Through Derailment of &agr;-Tubulin Proteostasis in Experimental and Human Atrial Fibrillation

  2014cited by this paper
• Mitochondrial dysfunction causing cardiac sodium channel downregulation in cardiomyopathy.

  2013cited by this paper
• PARP pairs up to PARsylate

  2012cited by this paper
• HSPB1, HSPB6, HSPB7 and HSPB8 Protect against RhoA GTPase-Induced Remodeling in Tachypaced Atrial Myocytes

  2011cited by this paper
• Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study).

  2011cited by this paper
• Effects of different small HSPB members on contractile dysfunction and structural changes in a Drosophila melanogaster model for Atrial Fibrillation.

  2011cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• Cardiac Na+ Current Regulation by Pyridine Nucleotides

  2009cited by this paper
• Nicotinamide Phosphoribosyltransferase Regulates Cell Survival Through NAD+ Synthesis in Cardiac Myocytes

  2009cited by this paper
• Exogenous NAD Blocks Cardiac Hypertrophic Response via Activation of the SIRT3-LKB1-AMP-activated Kinase Pathway*

  2009cited by this paper
• Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation.

  2008cited by this paper
• Cardiac Sodium Channel (SCN5A) Variants Associated with Atrial Fibrillation

  2008influential reference
• The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases.

  2008influential reference
• PARP mediates structural alterations in diabetic cardiomyopathy.

  2008cited by this paper
• ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

  2007cited by this paper
• Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

  2007influential reference
• Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.

  2007cited by this paper
• Induction of Heat Shock Response Protects the Heart Against Atrial Fibrillation

  2006cited by this paper
• Activation of the Poly(ADP-Ribose) Polymerase Pathway in Human Heart Failure

  2006cited by this paper
• Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.

  2005cited by this paper
• Poly(ADP-ribose) Polymerase-1-dependent Cardiac Myocyte Cell Death during Heart Failure Is Mediated by NAD+ Depletion and Reduced Sir2α Deacetylase Activity*

  2005cited by this paper
• Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme.

  2005cited by this paper
• Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure.

  2005cited by this paper
• Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1.

  2004cited by this paper
• The comet assay for DNA damage and repair

  2004cited by this paper
• Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation.

  2004cited by this paper
• Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation.

  2002cited by this paper
• Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1*

  2002cited by this paper
• New ideas about atrial fibrillation 50 years on

  2002cited by this paper
• Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure.

  2002cited by this paper
• The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors

  2002cited by this paper
• Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases

  2001cited by this paper
• Molecular adaptations in human atrial fibrillation Brundel

  2000cited by this paper
• Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis.

  1999cited by this paper
• Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle.

  1997cited by this paper
• Serveur Académique Lausannois SERVAL serval.unil.ch

  year unknowncited by this paper

• No citing papers are available for this paper.